Stay updated with breaking news from Teroid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scientists have found success in treating a 'neglected' inflammatory condition, polymyalgia rheumatica, with a drug that could provide an alternative to steroids for patients.
A recent study explores the potential benefits of utilizing duck fats in the food industry, highlighting their unique fatty acid composition and improved properties compared to vegetable oils. Duck fats offer a healthier alternative to saturated fats, making them a valuable resource for enhancing food products.
Scientists from La Jolla Institute for Immunology (LJI) and The University of Southampton, UK, have uncovered a group of immune cells that may drive severe asthma.
A first-of-its kind hormone replacement therapy that more closely replicates the natural circadian and ultradian rhythms of our hormones has shown to improve symptoms in patients with adrenal conditions.
Surgery to straighten a crooked septum (the thin wall of bone and cartilage dividing the space between the two nostrils) is more effective than nasal sprays, and should be offered to adults with at least moderate symptoms such as breathing disruption, suggests a UK trial published by The BMJ today.
A saline injection treatment widely used for calcific tendinopathy - a common, painful condition caused by a build-up of calcium in the rotator cuff tendons of the shoulder - provides no meaningful benefit over placebo, concludes a trial published by The BMJ today.
The study examined how vitamin D levels and vitamin D binding protein genotypes in both pregnant mothers and their children aged 3-5, impact early childhood neurodevelopment. Findings suggest that higher vitamin D concentrations in children were associated with better neurodevelopmental scores, with additional influences from sociodemographic factors and certain genetic variations.
A new study in Neuropsychopharmacology delves into the mechanisms of action of brexanolone, the first FDA-approved, rapid-acting antidepressant specifically for postpartum depression (PPD). The research highlights brexanolone's potential anti-inflammatory effects and its impact on GABAA receptors, offering insights into its efficacy and suggesting avenues for further study.